Related Experiment Video

Updated: Apr 27, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma

Sudy Jahangiri1, Jonathan Friedberg, Paul Barr

  • 1University of Rochester Medical Center , Rochester, NY , USA paul_barr@urmc.rochester.edu.

Expert Opinion on Emerging Drugs
|June 25, 2014
PubMed
Abstract

Insights

Novel protein kinase inhibitors (PKIs) show promise for treating non-Hodgkin's lymphoma (NHL). Further research and clinical trials are needed to optimize their use and manage potential side effects.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Non-Hodgkin's lymphoma (NHL) represents 4.3% of US cancer diagnoses.
  • A significant portion of NHL patients, even with curable subtypes, face disease progression.
  • There is a critical need for improved therapeutic strategies in NHL, particularly for indolent forms focused on quality of life.

Purpose of the Study:

  • To discuss signaling mechanisms in B-cells and their alterations in NHL.
  • To review novel protein kinase inhibitors (PKIs) targeting these pathways.
  • To explore the efficacy and combination strategies of PKIs in various NHL subtypes.

Main Methods:

  • Review of B-cell signaling pathways in normal and malignant states.
  • Analysis of preclinical and clinical data on novel protein kinase inhibitors (PKIs).
  • Exploration of rational combinations of PKIs with existing therapies.

Main Results:

  • PKIs target key signaling pathways dysregulated in NHL.
  • These agents demonstrate efficacy across aggressive and indolent NHL histologies.
  • Combination therapies involving PKIs are being investigated for enhanced outcomes.

Conclusions:

  • Protein kinase inhibitors (PKIs) are poised to transform NHL treatment paradigms.
  • Optimal PKI use will necessitate personalized approaches considering disease specifics, therapeutic goals, and costs.
  • Future trials must accommodate prolonged treatment durations and monitor for unique toxicities associated with novel pathway targeting.
Keywords:
B-cell receptoribrutinibidelalisibnon-Hodgkin lymphomaprotein kinase inhibitor

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K